Biotech News

Neurocrine Biosciences to Present Research Advancing Understanding of Prader-Willi Syndrome and Real-World Experience with VYKAT® XR (diazoxide choline) at Foundation for Prader-Willi Research Symposium & Family Conference

Neurocrine Biosciences (NBIX)Neurocrine BiosciencesConference / presentation

PWS-VISTA observational study will build longitudinal real-world evidence on VYKAT XR use for hyperphagia in Prader-Willi syndrome in routine clinical practice BRAVE-PWS observational study will capture caregiver-reported information to better understand the experience and burden of caring for

Related news

NBIXNeurocrine Biosciences2026-11-10 21:01 EST

Neurocrine Biosciences to Present at the 2026 Jefferies Global Healthcare Conference

NBIXNeurocrine Biosciences2026-10-22 20:05 EST

Neurocrine Biosciences Announces Publication in Orphanet Journal of Rare Diseases Advancing Understanding of Hyperphagia in Prader-Willi Syndrome

HRMYHarmony Biosciences2026-10-01 12:05 EST

Harmony Biosciences Announces Poster Presentation at the 17th European Narcolepsy Days

TEVATeva Pharmaceutical Industries2026-11-20 21:30 EST

Teva to Present at the 9th Annual Evercore Healthcare Conference, the Piper Sandler 38th Annual Healthcare Conference and Citi’s 2026 Global Healthcare Conference

HRMYHarmony Biosciences2026-11-19 13:05 EST

Harmony Biosciences to Participate in Upcoming Investor Conferences

VYGRVoyager Therapeutics2026-10-27 12:01 EST

Voyager’s Tau-Targeted Gene Therapy VY1706 and Anti-Tau Antibody VY7523 for Alzheimer’s Disease to Be Featured in Poster Presentations at CTAD 2026

CGTXCognition Therapeutics2026-11-09 12:30 EST

Cognition Therapeutics Invited to Participate in 2026 Jefferies Global Healthcare Conference

GANXGain Therapeutics2026-11-05 12:00 EST

Gain Therapeutics Announces Late-Breakers and Poster Presentations at Upcoming Scientific Conferences

GANXGain Therapeutics2026-11-17 21:15 EST

Gain Therapeutics Presents Clinical Data from Phase 1b Study of Rexaceract and Preclinical Data from Novel GCase Modulator GT-04686

TNXPTonix Pharmaceuticals2026-11-04 12:00 EST

Tonix Pharmaceuticals to Present at Guggenheim’s 3rd Annual Healthcare Innovation Conference

Neurocrine Biosciences

Neuroscience and Endocrinology Portfolio Neurocrine Biosciences discovers, develops and commercializes medicines for neuropsychiatric, neurological, endocrine and immunological disorders. Its business combines several first-in-class commercial products with a deep mid- and late-stage pipeline. Commercial Medicines The portfolio includes...

Recent company news

Stock data

Close
156.59 USD
Market cap
15.57B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States